| Previous Close | 148.40 |
| Open | 148.40 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 900 |
| Day's Range | 146.50 - 149.25 |
| 52 Week Range | 109.16 - 157.00 |
| Volume | 4,835,493 |
| Avg. Volume | 6,887,735 |
| Market Cap | 388.473B |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | 25.96 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 4.04 (2.72%) |
| Ex-Dividend Date | Aug. 24, 2020 |
| 1y Target Est | N/A |
- CNW Group
Panorama Capital Corp. announces LOI for qualifying transaction with U.S. based Avisa Pharma Inc.
KELOWNA, BC , May 13, 2020 /CNW/ - Panorama Capital Corp. (PANO-P.V) (the "Company" or "Panorama"), a capital pool company ("CPC"), is pleased to announce it has entered into a non-binding letter of intent dated May 12, 2020 (the "LOI") to enter into an arm's length business combination transaction (the "Proposed Transaction") with Avisa Pharma Inc. ("Avisa"). Established in 2010, Avisa is a private medical device company with its head office in Santa Fe, New Mexico and incorporated under the laws of the State of Delaware . Avisa has developed a quantitative, point-of-care diagnostic breath test known as the Avisa BreathTest ("ABT") for rapidly detecting bacterial pneumonia and pulmonary infections in approximately 10 minutes.
- ACCESSWIRE
Johnson & Johnson to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 14, 2020 / Johnson & Johnson (NYSE:JNJ) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on April 14, 2020 at 8:30 AM Eastern ...
CNW GroupJohnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
NEW BRUNSWICK, N.J., March 30, 2020 /CNW/ -- Johnson & Johnson (NYSE:JNJ - News) (the Company) today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of the Company's manufacturing capacity with the goal of providing global supply of more than one billion doses of a vaccine. The Company expects to initiate human clinical studies of its lead vaccine candidate at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021, a substantially accelerated timeframe in comparison to the typical vaccine development process.
